TY -的T1 -吸入糖皮质激素downregulate SARS-CoV-2-related genes in COPD: results from a randomised controlled trial JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.00130-2021 VL - 58 IS - 1 SP - 2100130 AU - Milne, Stephen AU - Li, Xuan AU - Yang, Chen Xi AU - Leitao Filho, Fernando Sergio AU - Hernández Cordero, Ana I. AU - Yang, Cheng Wei Tony AU - Shaipanich, Tawimas AU - van Eeden, Stephan F. AU - Leung, Janice M. AU - Lam, Stephen AU - Sin, Don D. Y1 - 2021/07/01 UR - //www.qdcxjkg.com/content/58/1/2100130.abstract N2 - Observational studies show that COPD is associated with increased coronavirus disease 2019 (COVID-19) severity and mortality [1]. Inhaled corticosteroids (ICS), which are commonly used to treat COPD, have been associated with increased risk of bacterial pneumonia in COPD and impaired immune response to viruses. Whether this class of medication affects the airway expression of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) receptors and cofactors (changes which may modify COVID-19 susceptibility and outcomes) is currently unclear. Therefore, we examined the effects of ICS treatment on SARS-CoV-2-related gene expression in lower airway bronchial epithelial cells (BECs) in a randomised controlled trial of COPD patients.In a RCT of 63 patients with COPD, 12 weeks of ICS/LABA therapy downregulated bronchial epithelial expression of the SARS-CoV-2-related genes ACE2 and ADAM17 compared to LABA alone. This may have implications for COVID-19 susceptibility/severity in COPD. https://bit.ly/3vZnBVOThe authors would like to thank the generous fundraising and donation efforts by Irving Ding and Chun Hong Tao to St. Paul's Foundation COVID-19 Response Fund. We are grateful to Ryan Vander Werff and Tara Stach at BRC-Seq (University of British Columbia (UBC), Vancouver, BC, Canada) for conducting the RNA sequencing; and Chung Cheung and Julia Yang (UBC Centre for Heart Lung Innovation) for their assistance with laboratory specimens. ER -